RE:RE:Seems to be room for others in AD Treatment Great question for the new CEO as it exemplifies the main failing of the old CEO to differentiate in a way suitable for retail investors. Such investors need a bold statement describing how the competition is limited by not utilizing fold-specific exposed epitopes, i.e., why the misfolding is critical. It's not enough to have the information available in academic papers or inferred from the totality of corporate presentations, the competition needs to be called out because that is what investors will understand.